公司
Model N supports the complex business needs of the world’s leading brands in pharmaceutical, medical device, high tech, manufacturing and semiconductors across more than 120 countries, including Pfizer, AstraZeneca, Sanofi, Gilead, Abbott, Stryker, AMD, Micron, Seagate, STMicroelectronics, NXP, Sesotec, and Southern States.
公司
Model N supports the complex business needs of the world’s leading brands in pharmaceutical, medical device, high tech, manufacturing and semiconductors across more than 120 countries, including Pfizer, AstraZeneca, Sanofi, Gilead, Abbott, Stryker, AMD, Micron, Seagate, STMicroelectronics, NXP, Sesotec, and Southern States.
公司
Model N supports the complex business needs of the world’s leading brands in pharmaceutical, medical device, high tech, manufacturing and semiconductors across more than 120 countries, including Pfizer, AstraZeneca, Sanofi, Gilead, Abbott, Stryker, AMD, Micron, Seagate, STMicroelectronics, NXP, Sesotec, and Southern States.
根据93%的高管,收入管理是企业至关重要。然而,71%相信他们的行业可以做出更好的工作优化收入活动,以最大限度地增长。导致这种断开的是什么?
2021年的收入报告揭示了高科技和生命科学产业面临的最大挑战。有些是正在进行的,如定价相关的挑战。其他人,例如政府变更和新的法规,预计将在2021年的影响力比平常更大。而不是出乎意料的是,当今收入管理的最大因素是Covid-19。
了解高科技和生命科学公司的300家收入高管如何处理挑战,他们认为最大的机会撒谎。立即下载报告。
本报告将讨论这些主题的调查结果:
感谢您对N的兴趣N.请提交表格,我们的销售团队将在24小时内与亚愽申请您联系。









我们将在24小时内回复您。